S&P 500   2,989.69 (-0.20%)
DOW   27,001.98 (-0.08%)
QQQ   193.04 (-0.25%)
AAPL   234.37 (-0.40%)
FB   189.55 (+0.35%)
MSFT   140.41 (-0.82%)
GOOGL   1,243.00 (+0.06%)
AMZN   1,777.43 (+0.57%)
CGC   19.73 (-1.84%)
NVDA   194.21 (-1.10%)
MU   45.16 (-2.80%)
BABA   177.12 (+1.04%)
GE   8.90 (+0.11%)
TSLA   259.75 (+0.72%)
AMD   30.81 (+0.29%)
T   37.79 (-0.29%)
F   9.07 (+0.00%)
ACB   3.61 (-3.99%)
PRI   123.87 (+0.16%)
NFLX   286.28 (+0.71%)
BAC   30.17 (+1.48%)
GILD   65.35 (+0.08%)
DIS   130.86 (+0.85%)
S&P 500   2,989.69 (-0.20%)
DOW   27,001.98 (-0.08%)
QQQ   193.04 (-0.25%)
AAPL   234.37 (-0.40%)
FB   189.55 (+0.35%)
MSFT   140.41 (-0.82%)
GOOGL   1,243.00 (+0.06%)
AMZN   1,777.43 (+0.57%)
CGC   19.73 (-1.84%)
NVDA   194.21 (-1.10%)
MU   45.16 (-2.80%)
BABA   177.12 (+1.04%)
GE   8.90 (+0.11%)
TSLA   259.75 (+0.72%)
AMD   30.81 (+0.29%)
T   37.79 (-0.29%)
F   9.07 (+0.00%)
ACB   3.61 (-3.99%)
PRI   123.87 (+0.16%)
NFLX   286.28 (+0.71%)
BAC   30.17 (+1.48%)
GILD   65.35 (+0.08%)
DIS   130.86 (+0.85%)
Log in

Zoetis Stock Price, News & Analysis (NYSE:ZTS)

$127.93
-0.78 (-0.61 %)
(As of 10/16/2019 04:00 PM ET)
Today's Range
$127.51
Now: $127.93
$129.14
50-Day Range
$119.82
MA: $125.55
$129.65
52-Week Range
$78.90
Now: $127.93
$130.20
Volume1.63 million shs
Average Volume2.10 million shs
Market Capitalization$61.09 billion
P/E Ratio40.87
Dividend Yield0.51%
Beta0.87
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.83 billion
Cash Flow$3.80 per share
Book Value$4.55 per share

Profitability

Net Income$1.43 billion

Miscellaneous

Employees10,000
Market Cap$61.09 billion
Next Earnings Date11/7/2019 (Confirmed)
OptionableOptionable

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.


Zoetis (NYSE:ZTS) Frequently Asked Questions

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Thursday, October 3rd. Investors of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share on Monday, December 2nd. This represents a $0.66 dividend on an annualized basis and a yield of 0.51%. The ex-dividend date of this dividend is Monday, October 21st. View Zoetis' Dividend History.

How will Zoetis' stock buyback program work?

Zoetis announced that its Board of Directors has approved a stock repurchase plan on Wednesday, December 12th 2018, which permits the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 4.7% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its stock is undervalued.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) posted its quarterly earnings data on Tuesday, August, 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.82 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. Zoetis's quarterly revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.77 EPS. View Zoetis' Earnings History.

When is Zoetis' next earnings date?

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Zoetis.

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Thursday, November 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of $3.53-3.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.49. The company issued revenue guidance of $6.18-6.28 billion, compared to the consensus revenue estimate of $6.19 billion.

What price target have analysts set for ZTS?

15 equities research analysts have issued 12-month price objectives for Zoetis' stock. Their predictions range from $86.00 to $145.00. On average, they expect Zoetis' stock price to reach $124.40 in the next year. This suggests that the stock has a possible downside of 2.8%. View Analyst Price Targets for Zoetis.

What is the consensus analysts' recommendation for Zoetis?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

Has Zoetis been receiving favorable news coverage?

Media stories about ZTS stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zoetis earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Zoetis.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,420,000 shares, an increase of 30.8% from the August 30th total of 3,380,000 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is presently 2.3 days. Currently, 0.9% of the shares of the stock are short sold. View Zoetis' Current Options Chain.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 68)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 47)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
  • Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include CIBC Private Wealth Group LLC (0.49%), Artemis Investment Management LLP (0.17%), Hexavest Inc. (0.08%), DAVENPORT & Co LLC (0.06%), Gofen & Glossberg LLC IL (0.06%) and Ferguson Wellman Capital Management Inc. (0.05%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

Which major investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Varma Mutual Pension Insurance Co, DAVENPORT & Co LLC, Decatur Capital Management Inc., Gateway Investment Advisers LLC, Enlightenment Research LLC, Douglas Lane & Associates LLC and IMS Capital Management. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

Which major investors are buying Zoetis stock?

ZTS stock was bought by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Copper Rock Capital Partners LLC, State of Alaska Department of Revenue, Park National Corp OH, Exane Derivatives, Pacer Advisors Inc., Dfpg Investments Inc. and Howard Capital Management. View Insider Buying and Selling for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $127.93.

How big of a company is Zoetis?

Zoetis has a market capitalization of $61.09 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.

What is Zoetis' official website?

The official website for Zoetis is http://www.zoetis.com/.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


MarketBeat Community Rating for Zoetis (NYSE ZTS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  709 (Vote Outperform)
Underperform Votes:  429 (Vote Underperform)
Total Votes:  1,138
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: Leveraged Buyout (LBO)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel